Compound for targeting, combining and/or degrading APOC3 mRNA and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a compound for targeting, combining and/or degrading APOC3mRNA and application of the compound. The compound is shown in the following formula: # imgabs0 #, wherein a group A is shown in the following formula: # imgabs1 #, a group B is a linking group, and a group C is a recruitment group of ribonuclease. The compound provided by the invention can significantly reduce drug side effects. In addition, RIBOTAC as a small molecule may enter a wider tissue range, and has the advantages of higher targeting property, small dosage and the like. By converting RNA binding small molecules into an effective and specific APOC3mRNA degradation agent, RC535 can bind to ribonuclease and activate the ribonuclease to cut a target, and the level of APOC3mRNA in an HEPG2 cell line is successfully reduced. Therefore, the compound has a good prospect in clinical treatment of cardiovascular diseases. 本发明属于医药技术领域，具体涉及一种靶向、结合和/或降解APOC3mRNA的化合物及其应用。